JP2000504579A - 高等真核細胞の形質移入のための組成物 - Google Patents

高等真核細胞の形質移入のための組成物

Info

Publication number
JP2000504579A
JP2000504579A JP9528984A JP52898497A JP2000504579A JP 2000504579 A JP2000504579 A JP 2000504579A JP 9528984 A JP9528984 A JP 9528984A JP 52898497 A JP52898497 A JP 52898497A JP 2000504579 A JP2000504579 A JP 2000504579A
Authority
JP
Japan
Prior art keywords
egla
composition according
peptide
composition
lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP9528984A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000504579A5 (enExample
Inventor
エルンシュト ワーグナー
カルル メヒトラー
アントワーヌ キクレール
Original Assignee
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2000504579A publication Critical patent/JP2000504579A/ja
Publication of JP2000504579A5 publication Critical patent/JP2000504579A5/ja
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP9528984A 1996-02-15 1997-02-13 高等真核細胞の形質移入のための組成物 Abandoned JP2000504579A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19605548A DE19605548A1 (de) 1996-02-15 1996-02-15 Zusammensetzung für die Transfektion höherer eukaryotischer Zellen
DE19605548.2 1996-02-15
PCT/EP1997/000649 WO1997030170A1 (de) 1996-02-15 1997-02-13 Zusammensetzung für die transfektion höherer eukaryotischer zellen

Publications (2)

Publication Number Publication Date
JP2000504579A true JP2000504579A (ja) 2000-04-18
JP2000504579A5 JP2000504579A5 (enExample) 2004-11-18

Family

ID=7785445

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9528984A Abandoned JP2000504579A (ja) 1996-02-15 1997-02-13 高等真核細胞の形質移入のための組成物

Country Status (6)

Country Link
EP (1) EP0900281A1 (enExample)
JP (1) JP2000504579A (enExample)
CA (1) CA2246227A1 (enExample)
DE (1) DE19605548A1 (enExample)
MX (1) MX9805507A (enExample)
WO (1) WO1997030170A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2766705B1 (fr) * 1997-07-30 2001-05-25 Biovector Therapeutics Complexe particulaire de charge globale neutre ou negative forme d'une vesicule cationique ou neutre et d'une substance biologiquement active anionique, leur preparation et leur utilisation
FR2766706B1 (fr) * 1997-07-30 2001-05-25 Biovector Therapeutics Sa Complexes particulaires stables de charge globale neutre ou negative de structure multilamellaire composes par au moins une substance biologiquement active globalement anionique et un constituant cationique, leur preparation et utilisation
GB9918670D0 (en) 1999-08-06 1999-10-13 Celltech Therapeutics Ltd Biological product
GB0120022D0 (en) * 2001-08-16 2001-10-10 Photobiotics Ltd Conjugate
ES2646669T3 (es) 2010-07-06 2017-12-14 Glaxosmithkline Biologicals Sa Procedimientos de aumento de una respuesta inmunitaria mediante el suministro de ARN
SI2591114T1 (sl) 2010-07-06 2016-10-28 Glaxosmithkline Biologicals S.A. Imunizacija velikih sesalcev z majhnimi odmerki RNA
AU2011276234B2 (en) 2010-07-06 2016-02-25 Glaxosmithkline Biologicals S.A. Liposomes with lipids having an advantageous pKa- value for RNA delivery
WO2012031043A1 (en) 2010-08-31 2012-03-08 Novartis Ag Pegylated liposomes for delivery of immunogen-encoding rna
EP3520813B1 (en) 2010-10-11 2023-04-19 GlaxoSmithKline Biologicals S.A. Antigen delivery platforms
EP3854413A1 (en) 2011-07-06 2021-07-28 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
EP4014966A1 (en) 2011-07-06 2022-06-22 GlaxoSmithKline Biologicals S.A. Liposomes having useful n:p ratio for delivery of rna molecules
WO2013051718A1 (ja) 2011-10-07 2013-04-11 国立大学法人三重大学 キメラ抗原受容体
AU2016301196B2 (en) 2015-08-06 2022-09-08 Dana-Farber Cancer Institute, Inc. Tunable endogenous protein degradation
US11052111B2 (en) 2015-12-08 2021-07-06 Chimera Bioengineering, Inc. Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses
EP4342978A3 (en) 2016-09-01 2024-07-03 Chimera Bioengineering Inc. Gold optimized car t-cells
EP3580212A4 (en) 2017-02-08 2021-03-17 Dana Farber Cancer Institute, Inc. REGULATION OF CHEMERIC ANTIGEN RECEPTORS
US20240216509A1 (en) 2018-05-07 2024-07-04 Children's Hospital Medical Center Chimeric polypeptides, nucleic acid molecules, cells, and related methods
JPWO2020213724A1 (enExample) 2019-04-19 2020-10-22
JPWO2020246563A1 (enExample) 2019-06-05 2020-12-10
CN116194124A (zh) 2020-07-31 2023-05-30 中外制药株式会社 包含表达嵌合受体的细胞的药物组合物
US20240150472A1 (en) 2021-03-17 2024-05-09 Daiichi Sankyo Company, Limited Gene coding for chimeric receptor for anti-acetylcholine receptor autoantibody
US20240366666A1 (en) 2021-04-08 2024-11-07 Phosphogam, Llc Methods and compositions for enhancing the cytotoxicity of gamma/delta-t cells
WO2024150525A1 (ja) 2023-01-12 2024-07-18 国立大学法人山口大学 抗ネコｐｄ－１抗体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5578475A (en) * 1993-07-12 1996-11-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
FR2714830B1 (fr) * 1994-01-10 1996-03-22 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
US5928944A (en) * 1994-02-04 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method of adenoviral-medicated cell transfection
EP0874910A4 (en) * 1995-06-07 1999-04-21 Life Technologies Inc ENHANCED CATIONIC LIPID TRANSFECTION BY PEPTIDES
IL115199A (en) * 1995-09-07 2005-05-17 Opperbas Holding Bv Composition comprising a polynucleic acid molecule in a liposome and method using said composition

Also Published As

Publication number Publication date
WO1997030170A1 (de) 1997-08-21
EP0900281A1 (de) 1999-03-10
DE19605548A1 (de) 1997-09-04
CA2246227A1 (en) 1997-08-21
MX9805507A (es) 1998-11-29

Similar Documents

Publication Publication Date Title
JP3525393B2 (ja) 脂質及び例えばリポソーム中でのその使用
AU738083B2 (en) Cationic amphiphile/ DNA complexes
JP3925815B2 (ja) 細胞に遺伝子を運搬するための多機能分子複合体
EP0799059B1 (en) Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules
US7507859B2 (en) Functional synthetic molecules and macromolecules for gene delivery
US6756054B1 (en) Polycationic sterol derivatives as transfection agents
US5719131A (en) Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules
CA2246227A1 (en) Composition for the transfection of higher eucaryotic cells
JP2001517939A (ja) ペプチドによって増強されるトランスフェクション
JP2538474B2 (ja) 生物学的活性分子の細胞内配達のための陽イオン脂質
AU731503B2 (en) Cationic amphiphile compositions for intracellular delivery of therapeutic molecules
WO1998002190A9 (en) Cationic amphiphile/dna complexes
JPH11506935A (ja) ペプチド増強カチオン脂質トランスフェクション
FR2759382A1 (fr) Nouveaux composes et compositions les contenant utilisables pour le transfert d'au moins une substance therapeutiquement active, notamment un polynucleotide, dans une cellule cible et utilisation en therapie genique
CZ147398A3 (cs) Nová transfekční činidla a jejich farmaceutická použití
CN101094691A (zh) 载体
WO1998043994A1 (en) Cationic amphiphiles for intracellular delivery of therapeutic molecules
Zhang et al. Hybrids of nonviral vectors for gene delivery
JP2009542582A (ja) 生物活性物質を細胞に送達するための物質および複合体
JP2005515990A (ja) 化合物
WO1999002190A1 (en) Organ-specific targeting of cationic amphiphile/retinoblastoma encoding dna complexes for gene therapy
US6331524B1 (en) Organ-specific targeting of cationic amphiphile / DNA complexes for gene therapy
EP1007003A1 (en) Cationic amphiphile compositions for intracellular delivery of therapeutic molecules
WO1998050416A1 (en) Cationic amphiphiles containing multiple steroid lipophilic groups
EP4480943A1 (en) New class of lipids for delivering active ingredients into cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040212

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20040915